This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murakami, I. Articles by Yokosaki, Y. Search for Related Content PubMed PubMed Citation Articles by Murakami, I. Articles by Yokosaki, Y.

p53 Gene Mutations Are Associated with Shortened Survival in Patients with Advanced Non-small Cell Lung Cancer: An Analysis of Medically Managed Patients¹

Departments of Internal Medicine and Laboratory Medicine, National Hiroshima Hospital, Higashi-Hiroshima 739-0041 [I. M., Y. Y.]; Second Department of Internal Medicine, Hiroshima University, School of Medicine, Hiroshima 734-8551 [K. H., S. I., M. Y.]; and Department of Statistics, Radiation Effects Research Foundation, Hiroshima 732-0815 [F. K.], Japan

Mutations in the p53 gene are common in many cancers. Nevertheless, the relationship between mutations of this tumor suppressor gene and patient survival in non-small cell lung cancer (NSCLC) remains unclear. Interpretation of prior studies of patient outcomes are complicated by the inclusion of both surgical and nonsurgical patients. To better isolate the potential effects of p53 gene mutations per se on tumor progression, we chose to examine patients with advanced disease in whom surgery was not performed (stages IIIA, IIIB, and IV). We have used PCR-denaturing gradient gel electrophoresis, a sensitive and specific method for the detection of a variety of p53 mutations in cytology or biopsy specimens, to evaluate the prognostic significance of p53 gene mutations in nonsurgical patients with advanced NSCLC. In 70 consecutive medical patients, p53 mutations were found in 29 cases (41%) at the time of initial diagnosis. Followed prospectively, patients with p53 mutations had a significantly reduced survival time after diagnosis than those without mutations (median survival, 17 versus 39 weeks; P = 0.0003) independent of other clinical factors. This abbreviated survival occurred in both patients who received chemotherapy (n = 39, P = 0.002) or best supportive care (n = 31, P = 0.018). These results indicate that mutations of the p53 gene in patients with NSCLC who do not undergo surgical resection portends a significantly worse prognosis.

This article has been cited by other articles:

				J. K. Park, Y. M. Chung, B.-G. Kim, Y.-A Yoo, B.-S. Yang, J. S. Kim, and Y. D. Yoo N'-(phenyl-pyridin-2-yl-methylene)-hydrazine carbodithioic acid methyl ester enhances radiation-induced cell death by targeting Bcl-2 against human lung carcinoma cells Mol. Cancer Ther., April 1, 2004; 3(4): 403 - 407. [Abstract] [Full Text] [PDF]

				J. Brognard, A. S. Clark, Y. Ni, and P. A. Dennis Akt/Protein Kinase B Is Constitutively Active in Non-Small Cell Lung Cancer Cells and Promotes Cellular Survival and Resistance to Chemotherapy and Radiation Cancer Res., May 1, 2001; 61(10): 3986 - 3997. [Abstract] [Full Text]